Appleman, Leonard J.
UPMC Health System · UPMC Hillman Cancer Center · University of Pittsburgh Medical Center
3 papers on CoChatORCID 0000-0003-4951-7388
Most cited papers
- Verified
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine
Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism
Cited by 305
- Verified
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
Kelly, W. K., Danila, D. C., Lin, C.-C., Lee, J.-L., Matsubara, N., Ward, P. J., Armstrong, A. J., Pook, D., Kim, M., Dorff, T. B., et al. (2024) · Cancer Discovery
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 125
- Verified
A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following abiraterone and/or enzalutamide (abi/enz).
Petrylak, D. P., Vogelzang, N. J., Chatta, G. S., Fleming, M. T., Smith, D. C., Appleman, L. J., Hussain, A., Modiano, M., Singh, P., Tagawa, S. T., et al. (2015) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 25
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free